Another Major Order After Lilly: Celltrion Signs 294.9 Billion Won CMO Contract
Supplying Biopharmaceutical Raw Materials for Three Years Starting Next Year
Order Backlog Already Reaches 1 Trillion Won in the First Quarter
Accelerating CDMO Business Expansion... Considering Additional Capacity Expansion
Celltrion is accelerating the expansion of its global CDMO (Contract Development and Manufacturing Organization) business by signing a contract with a global pharmaceutical company for the contract manufacturing (CMO) of biopharmaceutical raw materials worth approximately 300 billion won.
On March 17, Celltrion announced that it had signed a contract with a global pharmaceutical company for the contract manufacturing (CMO) of biopharmaceutical raw materials. Under this agreement, Celltrion will supply biopharmaceutical raw materials to the partner company for three years, from 2027 to 2029. The contract amount is approximately 294.9 billion won, and it could be expanded up to 375.4 billion won depending on future discussions between the two companies. Celltrion plans to complete production preparations ahead of schedule to ensure a stable supply for its client.
Celltrion stated, "Throughout the course of our biopharmaceutical business, we have consistently demonstrated high quality standards, stable supply capabilities, and efficient production process management skills," and added, "This contract was also secured as our excellent production quality and stable supply system, which meet global standards, received high evaluations from our client."
Celltrion's global CMO business has been growing rapidly since it officially announced its full-scale expansion last year. Earlier this year, Celltrion signed a CMO contract with U.S.-based Eli Lilly worth approximately 678.7 billion won, and with the latest agreement, the company's total cumulative CMO order backlog for the year has already reached 1 trillion won.
As inquiries for CDMO (Contract Development and Manufacturing Organization) collaborations from global pharmaceutical companies have recently increased, Celltrion is also working to strengthen its global sales and project management (PM) capabilities, mainly through its subsidiary, Celltrion BioSolutions.
In particular, Celltrion is highlighting its technology-driven business model as a key differentiator, going beyond simple manufacturing. A representative example is the 'formulation CMO' business, which provides external clients with subcutaneous injection (SC) formulation modification technology developed during the process of creating Remsima SC and Herzuma SC.
Currently, Celltrion has a total production capacity of 316,000 liters, including its Songdo facilities (Plants 1, 2, and 3; total 250,000 liters) and its Branchburg, New Jersey facility in the United States (66,000 liters). The company explained that as the global biopharmaceutical market expands and demand for stable manufacturing partners increases, interest in Celltrion's production capabilities is also growing.
However, if global sales of in-house products such as Zympentra expand and new products are launched, a significant portion of production capacity may be allocated to Celltrion's own products. Therefore, Celltrion is considering additional expansion of its domestic and overseas production facilities, taking into account both the increasing demand for CDMO services and the rise in in-house product manufacturing.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion representative commented, "This major CMO contract once again demonstrates the competitiveness of Celltrion's production quality and stable supply capabilities in the global market," adding, "We plan to actively secure additional production capacity, considering both the expansion of in-house product manufacturing and the growth of our CDMO business to meet global demand."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.